Credit Suisse Ag Novo Cure LTD Call Options Transaction History

Credit Suisse Ag

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2020 Feb 12, 2021	SELL	$112.16 - $174.14 $11,216 - $17,414	-100 Reduced 0.2%	51,000 $8.83 Million
Q3 2020 Nov 13, 2020	BUY	$58.05 - $111.31 $2.79 Million - $5.34 Million	48,000 Added 1548.39%	51,100 $5.69 Million
Q4 2019 Feb 12, 2020	SELL	$68.3 - $93.8 $18.6 Million - $25.5 Million	-271,900 Reduced 98.87%	3,100 $261,000
Q2 2019 Aug 14, 2019	BUY	$42.22 - $63.23 $3.17 Million - $4.74 Million	75,000 Added 37.5%	275,000 $17.4 Million
Q1 2019 May 14, 2019	BUY	$31.96 - $56.12 $6.39 Million - $11.2 Million	200,000 New	200,000 $9.63 Million

290

75.6M

1.77M

538K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $2.27B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.